Metrizoic acid

Metrizoic acid is an organoiodine compound that has seen application as a contrast medium in radiological imaging. Its use in the medical field has been substantial, though it's important to recognize the inherent risks associated with its administration due to its high osmolality.

Chemical and Physical Properties[edit | edit source]

Metrizoic acid is classified under the umbrella of ionic, high osmolality contrast agents. These agents inherently contain a high number of particles in solution, leading to its high osmolality. This characteristic is a critical determinant in its biological behavior and associated risks^[1].

Clinical Applications[edit | edit source]

Metrizoic acid has been utilized in a variety of diagnostic imaging processes including:

Computed tomography (CT) scans
Intravenous urography
Angiography
As a contrast agent, it serves to enhance the differentiation between tissues, thereby improving the clarity and quality of imaging^[2].

Risks and Adverse Effects[edit | edit source]

While Metrizoic acid has been a valuable tool in radiological imaging, it's not without its concerns. The high osmolality of Metrizoic acid makes it more hypertonic compared to the plasma. This difference in osmolality is linked with a higher risk of inducing allergic reactions, especially when compared to lower osmolar or non-ionic contrast media^[3]. Reactions can range from mild (e.g., rash, itching) to severe, including anaphylaxis.
Healthcare providers should be equipped with the necessary tools and medications to address such reactions, ensuring patient safety. Moreover, thorough patient history, especially regarding allergies and prior contrast media reactions, can help in identifying those at elevated risk.

Conclusion[edit | edit source]

Metrizoic acid, with its distinctive chemical properties and osmolality, has played a crucial role in radiological imaging. It is, however, paramount for medical professionals to understand its associated risks and to be vigilant during its administration to ensure both effective imaging and patient safety.

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

‎

References[edit | edit source]

Strickland, N. H. (1991). Ionic and non-ionic iodinated contrast media: a perspective. Radiography, 57(1), 13-17.
Dawson, P., & Clauss, W. (1999). Ionic and nonionic contrast media – mechanisms and consequences. European Journal of Radiology, 29, S44-S47.
Barrett, B. J., & Carlisle, E. J. (1993). Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology, 188(1), 171-178.

↑ Strickland, N. H. (1991). Ionic and non-ionic iodinated contrast media: a perspective. Radiography, 57(1), 13-17.
↑ Dawson, P., & Clauss, W. (1999). Ionic and nonionic contrast media – mechanisms and consequences. European Journal of Radiology, 29, S44-S47.
↑ Barrett, B. J., & Carlisle, E. J. (1993). Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology, 188(1), 171-178.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

[1] Strickland, N. H. (1991). Ionic and non-ionic iodinated contrast media: a perspective. Radiography, 57(1), 13-17.

[2] Dawson, P., & Clauss, W. (1999). Ionic and nonionic contrast media – mechanisms and consequences. European Journal of Radiology, 29, S44-S47.

[3] Barrett, B. J., & Carlisle, E. J. (1993). Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology, 188(1), 171-178.

[1]

[2]

[3]